Optiver Holding
RCUS icon

Optiver Holding’s Arcus Biosciences RCUS Stock Holding History

Optiver Holding’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.42K Buy
297
+86
+41% +$1.86K ﹤0.01% 1335
2025
Q4 		$5.03K Sell
211
-461
-69% -$9.4K ﹤0.01% 1370
2025
Q3 		$9.14K Buy
+672
New +$6.99K ﹤0.01% 1356

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Optiver Holding's RCUS Position: Q1 2026 in Review

Optiver Holding increased its Arcus Biosciences (RCUS) stake by 41% in Q1 2026, buying an estimated $1.86K and bringing the position to 297 shares worth $6.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

Optiver Holding first reported a position in RCUS in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.14K in Q3 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Optiver Holding held 297 shares of Arcus Biosciences worth $6.42K as of Q1 2026.
  • Optiver Holding bought 86 Arcus Biosciences shares in Q1 2026, an estimated $1.86K.
  • Arcus Biosciences made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1335 holding.
  • Optiver Holding first reported a position in Arcus Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Arcus Biosciences position peaked at $9.14K in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.